# This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

> **NCT03780608** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 61 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Malignant Melanoma

## Interventions

- **DRUG:** AZD6738
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03780608
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-30
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780608, "This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03780608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*